Device Neuro Pain (Includes Interventional)

Osteocool Rf Ablation System

Payments companies reported to CMS as associated with Osteocool Rf Ablation System. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$799Kassociated payments (2023-2025)
2,348clinicians with associated payments
1company reporting

By year

2023 $339K
2024 $309K
2025 $151K

Payments reported as associated with Osteocool Rf Ablation System, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Vascular & Interventional Radiology $273K
Diagnostic Radiology $102K
Orthopaedic Surgery $74K
Pain Medicine (Anesthesiology) $63K
Radiation Oncology $46K
Neurological Surgery $32K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Osteocool Rf Ablation System

These are the largest totals companies reported as associated with Osteocool Rf Ablation System. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Jason Levy Atlanta, GA Vascular & Interventional Radiology $99,509.12
Jonathan Morris Rochester, MN Diagnostic Radiology $58,997.53
Labib Haddad Saint Louis, MO Vascular & Interventional Radiology $42,441.41
Amir Lavaf Palm Springs, CA Radiation Oncology $39,191.49
Theresa Pazionis Philadelphia, PA Sports Medicine (Orthopaedic Surgery) $32,220.25
Matthew Cable New Orleans, LA Orthopaedic Surgery $30,422.46
Thomas Andreshak Sylvania, OH Orthopaedic Surgery $24,301.32
Dipak Ramkumar Phoenix, AZ Surgical Oncology $16,723.90
Rahul Sheth Houston, TX Vascular & Interventional Radiology $13,424.09
Asad Baig New York, NY Vascular & Interventional Radiology $12,987.33

Prescribed Osteocool Rf Ablation System?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.